|  |  |
| --- | --- |
| **Committee:** | Extra HDEC Subcommittee |
| **Meeting date:** | 30 November 2021 |
| **Zoom details:** | <https://mohnz.zoom.us/j/96507589841> |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Time** | **Review Reference** | **Project Title** | **Coordinating Investigator** | **Lead Reviewers** |
| 12.30-1.00pm | 2021 FULL 11775 | A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients with Progressing Open Angle Glaucoma (ONL1204-OAG-001) | Professor Anthony Wells | Ms Catherine Garvey & Dr Patries Herst |
| 1.00-1.30pm | 2021 FULL 11729 | GO43643: An Open-Label Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin in Participant with Aggressive B-Cell Non Hodgkin's Lymphoma | Dr Samar Issa | Mrs Helen Walker & Mr Barry Taylor |
| 1.30-2.00pm | 2021 FULL 11758 | A Phase 2a, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of AT-1501 in Patients with IgA Nephropathy | Dr Kannaiyan Rabindranath | Mr Anthony Fallon & Dr Patries Herst |
| 2.00-2.30pm | 2021 FULL 11152 | Cytisine and e-cigarettes study with supportive text-messaging | Associate Professor Natalie Walker | Ms Catherine Garvey & Mr Barry Taylor |
| 2.30-2.40pm |  | *Break (10 minutes)* |  |  |
| 2.40-3.10pm | 2021 EXP 11418 | Physical activity and health: The effect of GoldFit YMCA participation on the brain, breathing and blood pressure regulation | Miss Thalia Babbage | Mrs Helen Walker & Dr Patries Herst |
| 3.10-3.40pm | 2021 FULL 11564 | GLOBAL - MIRACLE 2 STUDY | Doctor Satpal Singh Arri | Mr Anthony Fallon & Mr Barry Taylor |
| 3.40-4.10pm | 2021 FULL 11338 | Study of Tesomet in Adult and Adolescents with Prader-Willi Syndrome | Professor Paul Hofman | Ms Catherine Garvey & Dr Patries Herst |
| 4.10-4.40pm | 2021 FULL 11749 | CN42097\_A Clinical Trial to Examine if an Injection of Ocrelizumab Under the Skin is a Safe and Effective Alternative Way of Treating Patients with Multiple Sclerosis (MS) | Dr Jennifer Pereira | Mrs Helen Walker & Mr Barry Taylor |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Member Name** | **Member Category** | **Appointed** | **Term Expires** | **Apologies?** |
| Ms Catherine Garvey (chair) | Law (the law) | 11/08/2021 | 11/08/2023 | Present |
| Mrs Helen Walker | Lay (consumer/community perspectives) | 22/05/2020 | 22/05/2023 | Present |
| Mr Anthony Fallon | Lay (consumer/community perspectives) | 13/08/2021 | 13/08/2024 | Present |
| Dr Patries Herst | Non-lay (intervention studies) | 22/05/2020 | 22/05/2023 | Present |
| Mr Barry Taylor | Non-lay (intervention/observation studies) | 13/08/2021 | 16/08/2024 | Present |

## Welcome

Ms Catherine Garvey was selected as Chair for this Subcommittee meeting.

The Chair opened the meeting at 12.00pm and welcomed Committee members.

The Chair noted that the meeting was quorate.

The Committee noted and agreed the agenda for the meeting.

## New applications

|  |  |  |
| --- | --- | --- |
| **1** | **Ethics ref:** | **2021 FULL 11775** |
|  | Title: | A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients with Progressing Open Angle Glaucoma (ONL1204-OAG-001) |
|  | Principal Investigator: | Professor Anthony Wells |
|  | Sponsor: | ONL Therapeutics, Inc |
|  | Clock Start Date: | 19 November 2021 |

The investigators were not present for discussion of this application.

Potential conflicts of interest

The Chair asked members to declare any potential conflicts of interest related to this application.

No potential conflicts of interest related to this application were declared by any member.

Summary of Study

1. The purpose of this study is to demonstrate safety and tolerability of ONL1204 Ophthalmic Solution in patients with progressing open angle glaucoma. The study also aims to assess the efficacy and the pharmacokinetics of ONL1204 Ophthalmic Solution in male and female participants aged 18 years and older.

Summary of outstanding ethical issues

The main ethical issues considered by the Committee and which require addressing by the Researcher are as follows.

1. The Committee requested clarification around the number of participants in the trial, specifically, the number of which are New Zealand-based.
2. The Committee explained that Te Tiriti o Waitangi should not be cited as a health benefit and equal access to participate for Māori should not need to be stated as this is the default expectation. The Committee recommended more nuanced consideration and including any statistics of the prevalence of the disease in Māori (or an explanation if this is unknown) when answering C.4. for any future applications.
3. The Committee requested clarification of the statement in C.10, “…Participants have been receiving treatment on a feeder study.”. This appears inconsistent with the recruitment procedures described and the study design and as such the Committee would like further information.
4. The Committee requested that the Standing Committee on Therapeutic Trials (SCOTT) approval forms be provided.

The Committee requested the following changes to the Participant Information Sheet and Consent Form (PIS/CF):

1. Please remove references to the ”Industry Guidelines” given that reference to the Sponsor being a member of Medicines New Zealand has been removed, to avoid participant confusion.

**Decision**

This application was *provisionally approved* by consensus, subject to the following information being received:

1. Please address all outstanding ethical issues, providing the information requested by the Committee.
2. Please update the participant information sheet and consent form, taking into account feedback provided by the Committee. *(National Ethical Standards for Health and Disability Research and Quality Improvement, para 7.15 – 7.17).*
3. Please update the study protocol, taking into account the feedback provided by the Committee. (National Ethical Standards for Health and Disability Research and Quality Improvement, para 9.7).

After receipt of the information requested by the Committee, a final decision on the application will be made by Ms Catherine Garvey and Dr Patries Herst.

|  |  |  |
| --- | --- | --- |
| **2** | **Ethics ref:** | **2021 FULL 11729** |
|  | Title: | GO43643: An Open-Label Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin in Participant with Aggressive B-Cell Non Hodgkin's Lymphoma |
|  | Principal Investigator: | Dr Samar Issa |
|  | Sponsor: | F. Hoffmann-La Roche Ltd |
|  | Clock Start Date: | 18 November 2021 |

Dr Samar Issa and Olivia Lester were present via videoconference for discussion of this application.

Potential conflicts of interest

The Chair asked members to declare any potential conflicts of interest related to this application.

No potential conflicts of interest related to this application were declared by any member.

Summary of Study

1. The study will test the equality of Progression Free Survival (PFS) distribution in mosunetuzumab plus polatuzumab vedotin versus R-GemOx. The primary endpoint is PFS, defined as the time from randomization to the first occurrence of disease progression, as determined by the Independent Review Facility (IRF) with use of the Lugano 2014 Response criteria, or death from any cause, whichever occurs first.

Summary of resolved ethical issues

The main ethical issues considered by the Committee and addressed by the Researcher are as follows.

1. The investigator indicated it was unlikely there would be leftover tissue for optional biobanking after the Committee raised questions over insufficient detail provided for biobanking, which the optional tissue consent relates to.
2. The Committee queried if the collection of tissue for the biobank could be consented only in the event that there was additional tissue. The researcher informed the Committee that the consenting would not be done in this manner as it was impractical and not in keeping with the ethical standards they seek to uphold.
3. The investigator confirmed the process for dealing with findings of clinical significance in the genomic sequencing to be carried out as part of the study.

Summary of outstanding ethical issues

The main ethical issues considered by the Committee and which require addressing by the Researcher are as follows.

1. The Committee requested the optional consenting for the biobanking to be submitted as an amendment once the researcher and the sponsor come to a consensus around the necessity and practicality of collecting tissue for future optional research. Further, if the Sponsor does intend to request tissue for future unspecified research be donated to the Roche Research Biosample Repository (RBR) then further information is required to ensure that the guidelines for tissue banks are met (National Ethical Standards, Chapter 15).

The Committee requested the following changes to the Participant Information Sheet and Consent Form (PIS/CF):

1. Please include information and a section in CF for the genetic testing and the delivery of significant clinical findings from this, to participants.
2. Please clarify the location of the Roche biorepository (RBR) used for storage of optional tissue storage should this become necessary. If unnecessary and no optional tissue collection should occur, remove mention and consenting for optional tissue collection.

**Decision**

This application was *approved* by consensus, subject to the following non-standard conditions:

* please address all outstanding ethical issues raised by the Committee
* please update the Participant Information Sheet and Consent Form, taking into account the feedback provided by the Committee. *(National Ethical Standards for Health and Disability Research and Quality Improvement, para 7.15 – 7.17)*
* any amendment to the optional tissue FUR PIS, and details relating to the RBR must be submitted to HDEC before that aspect of the study can proceed.

|  |  |  |
| --- | --- | --- |
| **3** | **Ethics ref:** | **2021 FULL 11758** |
|  | Title: | A Phase 2a, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of AT-1501 in Patients with IgA Nephropathy |
|  | Principal Investigator: | Dr Kannaiyan Rabindranath |
|  | Sponsor: | Eledon Pharmaceuticals, Inc. |
|  | Clock Start Date: | 19 November 2021 |

The Investigators were not present for discussion of this application.

Potential conflicts of interest

The Chair asked members to declare any potential conflicts of interest related to this application.

No potential conflicts of interest related to this application were declared by any member.

Summary of Study

1. The study will evaluate the safety and effectiveness of an investigational drug called AT-1501. It is a synthetic protein called a monoclonal antibody that is hoped to mitigate the effects of the body's immune system on the kidneys in participants with Immunoglobin A Nephropathy (IgAN). The primary objective of this study is to determine whether AT-1501 can reduce proteinuria in patients with IgAN at 24 weeks.

Summary of outstanding ethical issues

The main ethical issues considered by the Committee and which require addressing by the Researcher are as follows.

1. The Committee requested the number of New Zealand participants be provided.
2. The Committee asked that there be clarification of the information around covid vaccinations, and any potential boosters given to participants and how this may impact their ability to participate. In particular, the Committee requested that the researcher confirm that participants may choose to receive a COVID-19 vaccination or not; but if they do so then a 30-day timeframe applies per the Participant Information Sheet (PIS).
3. The Committee requested the sponsor sign the necessary forms in the application.
4. The Committee requested consistency around the keeping of data for 10 or 25 years across all paperwork. The Committee notes that 10 years is the requirement by New Zealand law.
5. Please include the charters mentioned in the Data Management Plan (DMP) for approval and for the sake of future review by the HDEC.
6. Please include a cultural statement and information around incidence in Māori if applicable.

The Committee requested the following changes to the Participant Information Sheet and Consent Form (PIS/CF):

1. Please elaborate on details that are considered Non-Lay i.e. Electrocardiograms (ECGs).
2. Please include more information in both the PIS and Consent Form (CF) about the collection of samples for future research and under what circumstances these samples may be taken.
3. Please clarify the “surgical procedure” mentioned on page 9 and remove if an error.
4. Please clarify what biomarkers may be investigated on future unspecified research and revise to make more lay-friendly.
5. Please ensure that no new information is brought up in the CF without first being explained in the main body of the PIS.

**Decision**

This application was *provisionally approved* by consensus, subject to the following information being received:

1. Please address all outstanding ethical issues, providing the information requested by the Committee.
2. Please update the participant information sheet and consent form, taking into account feedback provided by the Committee. *(National Ethical Standards for Health and Disability Research and Quality Improvement, para 7.15 – 7.17).*
3. Please update the study protocol, taking into account the feedback provided by the Committee. (National Ethical Standards for Health and Disability Research and Quality Improvement, para 9.7).

After receipt of the information requested by the Committee, a final decision on the application will be made by Mr Anthony Fallon and Dr Patries Herst.

|  |  |  |
| --- | --- | --- |
| **4** | **Ethics ref:** | **2021 FULL 11152** |
|  | Title: | Cytisine and e-cigarettes study with supportive text-messaging |
|  | Principal Investigator: | A/Professor Natalie Walker |
|  | Sponsor: | University of Auckland |
|  | Clock Start Date: | 18 November 2021 |

Dr Natalie Walker and Dr Amanda Calder were present via videoconference for discussion of this application.

Potential conflicts of interest

The Chair asked members to declare any potential conflicts of interest related to this application.

No potential conflicts of interest related to this application were declared by any member.

Summary of Study

1. The study plans to undertake a pragmatic, community-based, randomised clinical trial to determine whether combining cytisine with nicotine e-cigarettes will help more people quit smoking, compared to cytisine alone or nicotine e-cigarettes alone. All participants will also receive smoking cessation behavioural support delivered by text messaging.

Summary of resolved ethical issues

The main ethical issues considered by the Committee and addressed by the Researcher are as follows.

1. The Committee was concerned with the management of participants and the management of mental health. The researcher responded that there are processes in place and questions in the initial questionnaire that prompts additional support lines. There are other lines of contact also made available to at-risk participants upon signing up to the study.
2. The Committee clarified the individualisation of the texting system for behavioural intervention. The tailoring to individuals is a reference to the use of the participant’s name in text messaging and messages that align with their progress through the study. Further information and access to more tailored information can be provided with inputs as detailed in the Patient Information Sheet (PIS).
3. The Committee clarified that Te Reo Māori translation of the PIS and Te Reo speaking-research assistants were being sought for the study.

Summary of outstanding ethical issues

The main ethical issues considered by the Committee and which require addressing by the Researcher are as follows.

1. The Committee queried the escalation pathway in the event of harm coming to a participant or in the event of adverse reactions to the study interventions. The Researchers will provide the pharmacovigilance document that outlines the escalation pathway.
2. The Researcher queried what would be required for the application in the case of using online tools for the collection of reports for adverse reactions/events (AE) by the Centre for Adverse Reactions Monitoring (CARM) (in addition to the planned AE data collection through the study). The Committee requested that they be able to review this and that the use of the tools and how the tools will be monitored. Any reference to reporting to CARM that will be linked to the study, and the means of reporting AEs by way of the study’s own online reporting tool needs to be included in the PIS.
3. The Committee queried the risks with pregnancy in the study. Please clearly state how this will be reported by the participants and that there is no evidence on the effect of cytisine in pregnant humans and babies.
4. The Committee requested the eDiary that is to be used for AE reporting be submitted for approval.
5. The Committee requested more information and documented safety assurances around the I.D. process for delivery of the e-cigarettes to the participants. This is to provide some reassurance that the study interventions are received by the participant and not another member of the household.

The Committee requested the following changes to the Participant Information Sheet and Consent Form (PIS/CF):

1. Please include information for Auckland participants about the carbon monoxide testing. In particular, please advise the timeframe within which this is to occur on the participant’s completion of the study.
2. If there are side effects from the use of eCigarettes (vaping) outside of coughing and mouth irritation that people are likely to be concerned about or are more likely to occur, or other risks or significant unknown matters relating to vaping, please include this information in the PIS rather than solely relying on referring participants to a website.
3. Please include a separate consent form in the event of pregnancy post-birth and future follow up and supply this as an amendment if and when this is required.
4. Please review the PIS for consistency and clarity.
5. Please consider if you can include a more flow-chart oriented and less verbose version of the PIS in the events of participants of varied literacy and numeracy ability.

**Decision**

This application was *provisionally approved* by consensus, subject to the following information being received:

1. Please address all outstanding ethical issues, providing the information requested by the Committee.
2. Please update the participant information sheet and consent form, taking into account feedback provided by the Committee. *(National Ethical Standards for Health and Disability Research and Quality Improvement, para 7.15 – 7.17).*

After receipt of the information requested by the Committee, a final decision on the application will be made by Ms Catherine Garvey and Mr Barry Taylor.

|  |  |  |
| --- | --- | --- |
| **5** | **Ethics ref:** | **2021 EXP 11418** |
|  | Title: | Physical activity and health: The effect of GoldFit YMCA participation on the brain, breathing and blood pressure regulation |
|  | Principal Investigator: | Miss Thalia Babbage |
|  | Sponsor: | University of Auckland |
|  | Clock Start Date: | 19 November 2021 |

Thalia Babbage was present via videoconference for discussion of this application.

Potential conflicts of interest

The Chair asked members to declare any potential conflicts of interest related to this application.

No potential conflicts of interest related to this application were declared by any member.

Summary of Study

1. The primary objective is to obtain recordings of blood pressure, respiration and cerebral blood flow in older adults who are undergoing a community-based exercise training programme (GoldFit, YMCA) to observe whether community-based exercise training is associated with attenuated central and peripheral chemoreceptor sensitivity and tonicity.

Summary of outstanding ethical issues

The main ethical issues considered by the Committee and which require addressing by the Researcher are as follows.

1. The Committee noted that the advertising should refer to the 12 week participation component. Further, the statement of “no medical conditions” could be amended to “no severe medical conditions”.

The Committee requested the following changes to the Participant Information Sheet and Consent Form (PIS/CF):

1. Please include a picture of an older adult with the gear they will be wearing to illustrate what participation involves.
2. The Committee noted that the COVID-19 related Alert levels are being replaced with the Traffic Light framework and the section on this should be adjusted to reflect the new structure.

**Decision**

This application was *approved* by consensus, subject to the following non-standard conditions:

* please address all outstanding ethical issues raised by the Committee
* please update the Participant Information Sheet and Consent Form, taking into account the feedback provided by the Committee. *(National Ethical Standards for Health and Disability Research and Quality Improvement, para 7.15 – 7.17).*

|  |  |  |
| --- | --- | --- |
| **6** | **Ethics ref:** | **2021 FULL 11564** |
|  | Title: | GLOBAL - MIRACLE 2 STUDY |
|  | Principal Investigator: | Dr Satpal Sing Arri |
|  | Sponsor: | King’s College Hospital NHS Foundation Trust (KCH) |
|  | Clock Start Date: | 19 November 2021 |

Dr Satpal Sing Arri and Mandy Fish were present via videoconference for discussion of this application.

Potential conflicts of interest

The Chair asked members to declare any potential conflicts of interest related to this application.

No potential conflicts of interest related to this application were declared by any member.

Summary of Study

1. This International study will prospectively validate the MIRACLE2 score in patients admitted with out of hospital cardiac arrest (OOHCA). OOHCA remains a major public health issue and the MIRACLE2 score has the potential to guide clinicians to prioritise delivery of invasive, expensive and costly treatments to patients that will gain greatest benefit.

Summary of resolved ethical issues

The main ethical issues considered by the Committee and addressed by the Researcher are as follows.

1. The Committee found the waiver of consent was justified given the potential beneficial impact of the study and the feasibility to collect consent from patients (and wishing to avoid distress in family). The researcher further explained that a small percentage of the cohort who would have returned cognitive function would take an unknown amount of time and vary from person to person.

Summary of outstanding ethical issues

The main ethical issues considered by the Committee and which require addressing by the Researcher are as follows.

1. The Committee stated that the local data the study is wanting to collect, including ethnicity, needs to be detailed in study documentation, such as a protocol addendum that details what is being collected, how it is being used and how it will be stored for local rather than international registry purposes.
2. The National Ethical Standards require certain information for a registry. The registry does not appear to have been established yet at Kings College but information about prior work validating the Miracle2 score is available. The Committee should receive a copy of the governance structure of the data bank. The Committee noted the following standards (not all aspects are relevant): para 12.42, 12.43 & 12.44.
3. For Section 6.1 of the Data Management Plan (DMP), the Committee noted there should be something to address notification of privacy breach at an individual level. i,e if potentially identifiable information was accessed or unique identifier key stolen - individuals have a right to the breach being notified if alive.

**Decision**

This application was *provisionally approved* by consensus, subject to the following information being received:

1. Please address all outstanding ethical issues, providing the information requested by the Committee.
2. Please update the study protocol, taking into account the feedback provided by the Committee. (National Ethical Standards for Health and Disability Research and Quality Improvement, para 9.7).

After receipt of the information requested by the Committee, a final decision on the application will be made by Mr Anthony Fallon and Mr Barry Taylor.

|  |  |  |
| --- | --- | --- |
| **7** | **Ethics ref:** | **2021 FULL 11338** |
|  | Title: | Study of Tesomet in Adult and Adolescents with Prader-Willi Syndrome |
|  | Principal Investigator: | Professor Paul Hofman |
|  | Sponsor: | Saniona A/S |
|  | Clock Start Date: | 18 November 2021 |

No one was present via videoconference for discussion of this application.

Potential conflicts of interest

The Chair asked members to declare any potential conflicts of interest related to this application.

No potential conflicts of interest related to this application were declared by any member.

Summary of Study

1. Prader-Willi Syndrome is characterised by several genetic changes which result in a syndrome, one aspect of which is that a person with Prader-Willi does not feel full after a meal and they keep eating in a compulsive manner leading to obesity. This study is being conducted to test if a new drug called Tesomet has an effect on hyperphagia (feeling of excessive hunger) and is safe and well tolerated.

Summary of outstanding ethical issues

The main ethical issues considered by the Committee and which require addressing by the Researcher are as follows.

1. The Committee noted that not all documents uploaded were necessary and requested the researchers are more discerning when uploading documents.
2. The DMC Charter has not been uploaded, please provide this.
3. The Tissue Management Plan is a laboratory manual. The Committee recommended a combined Data and Tissue Management Plan (like the [template](https://ethics.health.govt.nz/assets/HDEC-data-tissue-management-template-Oct-2021.docx) on the HDEC website) for this study.
4. The Committee noted that the drug is associated with depression and suicidal ideation, and some questionnaires to be completed ask very explicit depression and suicidal ideation questions. The advice that a participant see their General Practitioner (GP) is inadequate compared to the risks described. The Committee recommended to include a counsellor, psychologist or psychiatrist associated with the trial in New Zealand who is aware this is happening and can support those who are at risk of suicide. If this drug increases these psychiatric side effects, there must be provisions made for support.
5. The Committee noted that there should be documentation of how a participant is assessed for their capacity to consent. Separately the protocol and participant information sheet (PIS) should describe how psychological distress is monitored and how any relevant psychological issues will be responded to.
6. In New Zealand, those aged 16 years and older can consent for themselves or have supported consent (6.6 – 6.10, 7.1-7.8), rather than have someone consent on their behalf with their assent. If participants over 16 cannot consent even with support, they should be excluded.
7. The Committee noted that the pregnancy Participant Information Sheet (PIS) is not reviewed as part of this submission and should be submitted as an amendment if a participant were to become pregnant.
8. The Committee noted that the uploaded Principal Investigator (PI) indemnity expired January 2021. An updated certificate is required.
9. If all New Zealand sites are using Firma, this needs to be made clear. The researcher should ensure they are familiar with the privacy policy of any third-party vendor that they are recommending or requiring participants to use.
10. Clarification is required whether it is mandatory for New Zealand participants to use the services of the Scarritt Group for reimbursement. There is no reference to this in the main PIS but reference to this occurs in the consent form of the main information sheet. There is also a separate information sheet for reimbursement which potentially imposes a burden on participants due to their requirements and the app for use is not mentioned. If this is mandatory, the Committee queried how participant burden will be reduced. If not please clarify the alternative means of reimbursement in the PIS.
11. The Open-label extension requires a separate information sheet rather than brief reference in the main participant information sheet and consent form. Circumstances may alter during the course of the main study which lead to different information being required describing the open label extension. Participants may be consented to continue prior to finishing the main study if it is important to not have a pause in the provision of study treatment, but this should be done by way of an amendment later during the course of the study.
12. Data management plan (DMP) needs to state that data is kept for 10 years once a participant reaches the age of 16 and consents to continue or for the continued use of their data.
13. The DMP needs to reflect assent and reconsent processes and include information on any third parties collecting data.

The Committee requested the following changes to the Participant Information Sheet and Consent Form (PIS/CF):

All

1. Please ensure all information is appropriate for New Zealand context (i.e. 111 for emergencies)
2. Please include information about the eDiary where applicable.
3. Please include information about the third party or overseas recipients of data where applicable.

13-15 PIS

1. There is not enough information in the 13-15 information sheet and would be more appropriate as a PIS for those who require supported assent.
2. The fact that this is completely voluntary should be stated after the first paragraph.
3. Needs to follow the form of the 16 and over: why is this study being done, what exactly does participation involve, how many pills a day, what happens during the visits, what happens to their information, who can they talk to about the trial other than parents/guardians.
4. There also needs to be an assent statement, signed and dated and a statement of the person who has obtained the assent.

Parent PIS

1. This PIS states “you are being asked to participate….because you have Prader-Willi syndrome” however this is for the parents to consent along with their child’s assent. Please ensure it is clear to parents/guardians the aspects of the study that relate to their child and the aspects of the study that require their own participation.
2. It mentions there are no treatments then says these options will be discussed with the participant. If there is no option, please remove this statement.

Adult PIS (16+)

1. In New Zealand, people 16 and older must consent for themselves for a clinical trial; another person, legal representative or otherwise cannot consent on their behalf.
2. There should be a consent item in the CF consenting for their whanau/caregiver to be approached to take part in this trial.
3. It seems that participation of the caregiver is mandatory. If someone does not wish for their caregiver to take part, then this person should be excluded.

Assent Adults

1. This form should be a supported consent Adult PIS for adult participants who are capable of giving informed consent with appropriate support.

Caregiver PIS

1. The Committee queried whether it is possible for the caregiver to be assaulted.

**Decision**

This application was *provisionally approved* by consensus, subject to the following information being received:

1. Please address all outstanding ethical issues, providing the information requested by the Committee.
2. Please update the participant information sheet and consent form, taking into account feedback provided by the Committee. *(National Ethical Standards for Health and Disability Research and Quality Improvement, para 7.15 – 7.17).*
3. Please update the study protocol, taking into account the feedback provided by the Committee. (National Ethical Standards for Health and Disability Research and Quality Improvement, para 9.7).

After receipt of the information requested by the Committee, a final decision on the application will be made by Ms Catherine Garvey and Dr Patries Herst.

|  |  |  |
| --- | --- | --- |
| **8** | **Ethics ref:** | **2021 FULL 11749** |
|  | Title: | CN42097\_A Clinical Trial to Examine if an Injection of Ocrelizumab Under the Skin is a Safe and Effective Alternative Way of Treating Patients with Multiple Sclerosis (MS) |
|  | Principal Investigator: | Dr Jennifer Pereira |
|  | Sponsor: | F. Hoffmann-La Roche Ltd |
|  | Clock Start Date: | 18 November 2021 |

Dr Jennifer Pereira, Diana Osavlyuk and Bronwyn Gale were present via videoconference for discussion of this application.

Potential conflicts of interest

The Chair asked members to declare any potential conflicts of interest related to this application.

No potential conflicts of interest related to this application were declared by any member.

Summary of Study

1. This study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of ocrelizumab in patients with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS).

Summary of resolved ethical issues

The main ethical issues considered by the Committee and addressed by the Researcher are as follows.

1. The Committee queried if the patients being targeted for recruitment will be mostly patients of the study team. The researcher clarified a lot of recruitment will be going through the MS Society to identify a large group not in regular contact with a neurologist and who could get benefit from this treatment. The Committee noted that it is preferable that recruitment is done through someone other than the co-ordinating investigator if it is their own patients to minimise risk of coercion.
2. It was confirmed with the researcher that participants in New Zealand would not be receiving home visits.

Summary of outstanding ethical issues

The main ethical issues considered by the Committee and which require addressing by the Researcher are as follows.

1. The optional submission of tissue to the Roche biorepository (RBR) does not have enough information in the optional information sheet/consent form, or anything publicly available with enough detail required by the National Ethical Standards (para 14.39 & 15.8). More information is required to be submitted to the Committee as well as made available to participants if the Sponsor wishes to receive tissue for optional future unspecified research.
2. There is a participant information sheet for MRI quality control (MRI Site Qualification) but their inclusion and role are not discussed elsewhere in the study documentation. Please ensure this is documented so that the Committee has detail regarding recruitment of healthy volunteers and management of incidental findings of clinical significance on MRI in the quality control.

The Committee requested the following changes to the Participant Information Sheet and Consent Form (PIS/CF):

1. Please include in the MRI Site Qualification PIS about how participants are selected, and the reporting of clinically significant findings.

**Decision**

This application was *approved* by consensus, subject to the following non-standard conditions:

* please address all outstanding ethical issues raised by the Committee
* please update the Participant Information Sheet and Consent Form, taking into account the feedback provided by the Committee.

## General business

1. **Matters Arising**
2. **Other business**

The Secretariat noted that as this was a special Subcommittee of members across several HDECs, the post-approval monitoring for all studies would be subsequently assigned to the Northern A HDEC upon the study receiving an Approval decision.

1. **Other business for information**
2. **Any other business**

The meeting closed at 4.40pm